Albert Einstein College of Medicine

NIH researchers developed TrialGPT, an AI algorithm that efficiently matches potential volunteers to relevant clinical trials on ClinicalTrials.gov, potentially enhancing clinical trial enrollment and medical research advancements.

NIH researchers developed TrialGPT, an AI algorithm to match potential volunteers to relevant clinical trials on ClinicalTrials.gov, enhancing trial enrollment efficiency and accuracy. The tool uses large language models to process patient summaries and identify eligible trials, reducing clinician screening time by 40% while maintaining accuracy. Selected for The Director's Challenge Innovation Award, TrialGPT aims to improve clinical trial recruitment and reduce participation barriers.

NIH developed AI algorithm TrialGPT matches potential volunteers to relevant clinical trials on ClinicalTrials.gov, improving enrollment efficiency and accuracy. TrialGPT processes patient summaries, identifies eligible trials, and explains eligibility criteria, saving clinicians 40% screening time. Selected for Director's Challenge Innovation Award to further assess real-world performance.

NIH developed AI algorithm, TrialGPT, matches potential volunteers to relevant clinical trials on ClinicalTrials.gov, saving clinicians time and accelerating research. TrialGPT processes patient summaries, identifies eligible trials, and explains eligibility criteria, achieving nearly the same accuracy as human clinicians. A pilot study showed clinicians using TrialGPT spent 40% less time screening patients with the same accuracy. The research team received a Director’s Challenge Innovation Award to further assess TrialGPT’s performance and fairness.

NIH researchers developed TrialGPT, an AI algorithm to match potential volunteers to clinical trials on ClinicalTrials.gov. TrialGPT processes patient summaries to identify and explain eligibility for relevant trials, reducing clinician screening time by 40% while maintaining accuracy. The tool aims to improve clinical trial enrollment and accelerate medical research.

Nerivio REN wearable, a non-drug therapy for acute migraine treatment, has received FDA clearance for use in children aged 8 years and older, becoming the first such therapy for this age group. The approval is based on a study showing safety and efficacy in children aged 6 to 11 years, with 72.2% reporting pain relief and 83.3% functional disability relief.

NGN-401, an AAV9 gene therapy delivering the full-length human MECP2 gene, showed positive interim data in Rett syndrome patients, with all low-dose cohort participants achieving 'much improved' status on CGI-I and significant improvements in RSBQ. The therapy demonstrated skill gains in core clinical areas, including hand function, language, and ambulation, with no signs of MECP2 overexpression toxicity. Neurogene plans to complete low-dose cohort enrollment by Q4 2024 and anticipates additional interim data in H2 2025.

The Precision Health and Longevity Summit 2024, to be held in Calgary, unites global experts to discuss health and longevity, aiming to make Canada a leader in these fields. The summit features discussions on AI, Genomics, and strategic policy, with a focus on personalized healthcare and longevity solutions. Key speakers include Dr. Dilpriya Kaur Mangat, Dr. David Barzilai, and Dr. Anmol Kapoor, among others. The event aims to drive equitable healthcare solutions and enhance the quality of life for Canadians.

The 'Transmucosal Drug Delivery Pipeline Report 2024 Update' from ResearchAndMarkets.com offers comprehensive insights into pipeline products, clinical trials, and key companies involved in Transmucosal Drug Delivery.

Neurogene reports positive interim efficacy data from the first four low-dose pediatric participants in its NGN-401 gene therapy clinical trial for Rett syndrome, showing meaningful gains in skills and developmental milestones. The therapy has demonstrated a favorable safety profile, with no treatment-related serious adverse events. Neurogene also initiates an adolescent/adult cohort and gains FDA alignment on CMC requirements for future registrational trials.